Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus...
PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium...
PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming...
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of...
The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 288.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...
• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently • Recruitment...
Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA,...
• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up•...
PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical...